Best Breast Cancer Doctors in Hyderabad — CION's Dedicated Breast Cancer Panel

The best doctor for breast cancer is a surgical oncologist with breast cancer experience (preferably female if you prefer), paired with a medical oncologist current with HER2-targeted therapy and CDK4/6 inhibitors, and a radiation oncologist. For women considering mastectomy, a reconstructive surgeon. At CION, every breast cancer case is reviewed by a multidisciplinary tumour board with female surgical, radiation, and medical oncology leadership: Dr. Paila Gowri Naidu (M.Ch BHU), Dr. Venkata Sushma P (MD SVIMS), and Dr. Bharati Devi Gorantla (DM Adyar Cancer Institute).

For most early-stage breast cancers (Stage I–II), breast-conserving surgery (lumpectomy + radiation) gives equivalent oncologic outcomes to mastectomy — same survival, same recurrence rates — while preserving the breast. Lumpectomy is the modern default where oncologically safe. Mastectomy is recommended when: multifocal disease (multiple tumours in different breast areas), unfavourable tumour-to-breast size ratio, prior radiation to the breast, BRCA mutation (often preferred), or patient preference. The conversation is yours — a team that explains the choice clearly and respects your decision is the right team.

Several options: (1) Immediate reconstruction (at the same operation as mastectomy) — often preferred for cosmetic and psychological outcomes; (2) Delayed reconstruction (months to years after mastectomy); (3) No reconstruction (going flat or external prosthesis) — also a valid choice. Reconstruction techniques: implant-based reconstruction (tissue expander followed by implant) — shorter operation, no donor site; autologous tissue reconstruction (DIEP flap, latissimus dorsi, TRAM, using your own tissue) — more natural feel, longer operation, longer recovery. CION coordinates reconstruction with accredited partner reconstructive surgery teams in Hyderabad.

Breast cancers are classified into molecular subtypes based on receptor status. HR+ (Hormone Receptor Positive, around 70% of cases) — ER and/or PR positive, HER2 negative. Treatment includes hormonal therapy (tamoxifen for premenopausal, aromatase inhibitors for postmenopausal) for 5–10 years ± CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) for high-risk or advanced disease. HER2+ (around 15–20%) — treated with trastuzumab + pertuzumab for ~1 year plus chemotherapy; T-DM1 for residual disease after neoadjuvant. Triple-Negative Breast Cancer (TNBC, around 10–15%) — aggressive subtype, treated with chemotherapy (anthracycline + taxane + platinum) ± immunotherapy (pembrolizumab) ± PARP inhibitor if BRCA-positive. ER/PR/HER2 testing is non-negotiable for breast cancer treatment planning.

BRCA1 and BRCA2 genetic testing is indicated if you have: strong family history of breast and/or ovarian cancer; age <40 at diagnosis; triple-negative breast cancer at any age; male breast cancer; bilateral breast cancer; Ashkenazi Jewish ancestry; or ovarian cancer at any age in a close relative. Positive BRCA1/2 status affects: treatment (PARP inhibitor eligibility — olaparib, talazoparib); surgical decisions (consideration of contralateral risk-reducing mastectomy); and family screening (siblings and children have a 50% chance of carrying the mutation). Genetic counselling before and after testing is essential. CION coordinates BRCA testing with partner genetic counselling services.

HER2 (Human Epidermal growth factor Receptor 2) overexpression occurs in 15–20% of breast cancers. HER2-positive disease was historically more aggressive — but is now highly treatable with HER2-targeted therapy that has transformed outcomes. First-line therapy: trastuzumab (Herceptin) + pertuzumab + chemotherapy as neoadjuvant or adjuvant. For residual disease after neoadjuvant: T-DM1 (Kadcyla — trastuzumab emtansine). For advanced/metastatic HER2+: trastuzumab-deruxtecan (Enhertu — T-DXd) has produced dramatic responses. Trastuzumab biosimilars are increasingly available and significantly reduce cost. CION delivers full HER2-targeted therapy per current NCCN guidelines.

Triple-negative breast cancer lacks ER, PR, and HER2 expression — making it ineligible for hormonal therapy and HER2-targeted therapy. TNBC is more common in young Indian women, BRCA mutation carriers, and tends to be aggressive. Treatment is primarily chemotherapy (anthracycline + taxane + platinum is commonly used in India). Pembrolizumab (immunotherapy) added to neoadjuvant chemotherapy for high-risk early TNBC has improved outcomes. PARP inhibitors (olaparib, talazoparib) for BRCA-positive TNBC. Despite the aggressive reputation, many TNBC patients achieve complete response and cure with modern treatment.

Yes — breast cancer treatment is covered under Aarogyasri for eligible patients in Telangana and Andhra Pradesh. Coverage includes surgery (lumpectomy, mastectomy), chemotherapy, radiation, hormonal therapy, and many targeted therapies (with some restrictions on the most expensive newer agents). CION is Aarogyasri-empanelled. Our team helps you understand what's covered, complete the documentation, and navigate the process. Patients have received substantial breast cancer treatment under Aarogyasri at CION.

A second opinion is valuable for breast cancer — particularly because surgical, reconstruction, and systemic therapy choices vary across centres, and because some centres still default to mastectomy when breast-conserving surgery would work. At CION the second opinion is free, written, and yours to keep — our multidisciplinary tumour board reviews your pathology, imaging, and existing recommendation and provides a documented opinion you can take anywhere.

Costs vary widely by stage, subtype, and treatment intensity. Lumpectomy + sentinel node biopsy ranges approximately ₹1,50,000 to ₹3,50,000. Modified radical mastectomy ₹2,00,000 to ₹4,00,000. Mastectomy with immediate reconstruction ₹4,00,000 to ₹8,00,000+. Adjuvant chemotherapy ₹2,00,000 to ₹6,00,000. Radiation therapy ₹2,00,000 to ₹4,00,000. Trastuzumab for HER2+ (1 year, including biosimilars) ₹2,00,000 to ₹10,00,000+ depending on biosimilar vs originator. Hormonal therapy for 5–10 years is relatively inexpensive. Aarogyasri coverage substantially reduces out-of-pocket cost for eligible patients. For a detailed cost breakdown, see our breast cancer treatment in Hyderabad page. Every CION patient receives a written, itemised cost estimate. Aarogyasri, EMI, and cashless insurance accepted.